Search
SOLACI Congress
HomePharmacologyAntiplatelet

Antiplatelet

View Category

Antiplatelet

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which...
Dr. Andrés Rodríguez -
Learn More
Antiplatelet

ESC 2024 | QUADRO Trial: Efficacy and Safety of the First Quadruple Therapy Single Pill in Resistant Hypertension Patients

Researchers conducted an international, randomized, parallel-group study with a superiority design over a 16-week period. The doses...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

ESC 2024 | AßYSS: Discontinuation of Beta-Blocker Treatment After One Year in Uncomplicated MI

Researchers presented a non-inferiority study conducted at 49 centers in France, with a randomized cohort of stable post-acute...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the...
solaci -
Learn More
Antiplatelet

Antiplatelet Treatment with Ticagrelor vs. Clopidogrel in Patients with Chronic Coronary Syndrome

Achieving rapid and maximum inhibition of platelet aggregation can reduce complications related to scheduled percutaneous coronary intervention...
solaci -
Learn More
Antiplatelet

Single Antiplatelet Therapy Following Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) has surged as an effective alternative to treat patients with atrial...
solaci -
Learn More
Antiplatelet

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor...
solaci -
Learn More
Acute coronary syndromes

Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2

Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Long Term Results of the International Chimney Registry

Dr. Omar Tupayachi - 0
The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

Dr. Omar Tupayachi - 0
The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

Dr. Omar Tupayachi - 0
The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

Institutional News

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy